Yadav Poonam, Shrestha Sreska, Sah Ranjit, Rai Junu Richhinbung, Kattel Hari Prasad, Sharma Sangita, Willcox Mark
Department of Microbiology, Tribhuvan University Teaching Hospital, Kathmandu, Nepal.
School of Optometry and Vision Science, Faculty of Medicine and Health, University of New South Wales, Sydney, Australia.
J Nepal Health Res Counc. 2025 Feb 14;22(4):662-669. doi: 10.33314/jnhrc.v22i04.4694.
Acinetobacter baumannii has emerged as a problematic pathogen due to its ability to become resistant to antibiotics and form biofilms. The aim of this study was to explore antibiotic resistance and biofilm formation, and examine any correlation between these in Acinetobacter baumannii isolates.
This was a cross-sectional study conducted at the 750-bed Tribhuvan University Teaching Hospital in Nepal. Identification and antibiotic sensitivity of Acinetobacter baumannii isolates were performed following American Society for Microbiology guidelines. Different β-lactamases were detected by standard phenotypic tests. The microtiter plate method was used to screen strains of their ability to form biofilms. Results: Out of total 18,343 clinical samples processed, 4,249 (23.1%) showed bacterial growth. A. baumannii comprised of 4.7% of the total bacterial growth. Multidrug-resistant (MDR) was exhibited by 97.5% of Acinetobacter baumannii isolates. All multidrug-resistant Acinetobacter baumannii isolates were resistant to cephalosporins and carbapenems; however, they were sensitive to polymyxins. Only few isolates showed sensitivity to sulbactam-containing antibiotics (15.4-29.2%), fluoroquinolones (1.0-7.2%), aminoglycosides (2.6-5.6%), and cotrimoxazole (4.1%). Extended-spectrum-beta-lactamase (ESBL), metallo-beta-lactamase (MBL), Klebsiella pneumoniae carbapenemase (KPC) and AmpC production were found in 54.9%, 73.3%, 41.5% and 14.9% isolates, respectively. Among all tested isolates, 192 were able to produce biofilms, with 83.1% being classified as strong biofilm producers. Those strains that were resistant to gentamicin were more likely to produce biofilms (P<0.05). ESBL, MBL, KPC and AmpC were seen in 51.8%, 71.6%, 43.8% and 16.0% of strong biofilm producers respectively.
Only polymyxins were effective against Acinetobacter baumannii. Carbapenemase producers were generally strong biofilm producers, and gentamicin resistant strains were more likely to produce biofilms. The findings of this study may help to understand antibiotic-resistance mechanisms and provide valuable information in the treatment of MDR Acinetobacter baumannii infections.
鲍曼不动杆菌因其对抗生素产生耐药性并形成生物膜的能力,已成为一种有问题的病原体。本研究的目的是探讨鲍曼不动杆菌分离株的抗生素耐药性和生物膜形成情况,并检查两者之间的相关性。
这是一项在尼泊尔拥有750张床位的特里布万大学教学医院进行的横断面研究。鲍曼不动杆菌分离株的鉴定和抗生素敏感性检测按照美国微生物学会指南进行。通过标准表型试验检测不同的β-内酰胺酶。采用微量滴定板法筛选菌株形成生物膜的能力。结果:在总共处理的18343份临床样本中,4249份(23.1%)显示有细菌生长。鲍曼不动杆菌占总细菌生长量的4.7%。97.5%的鲍曼不动杆菌分离株表现出多重耐药性(MDR)。所有多重耐药的鲍曼不动杆菌分离株对头孢菌素和碳青霉烯类耐药;然而,它们对多粘菌素敏感。只有少数分离株对含舒巴坦的抗生素(15.4 - 29.2%)、氟喹诺酮类(1.0 - 7.2%)、氨基糖苷类(2.6 - 5.6%)和复方新诺明(4.1%)敏感。分别在54.9%、73.3%、41.5%和14.9%的分离株中检测到超广谱β-内酰胺酶(ESBL)、金属β-内酰胺酶(MBL)、肺炎克雷伯菌碳青霉烯酶(KPC)和AmpC的产生。在所有测试的分离株中,192株能够产生生物膜,其中83.1%被归类为强生物膜产生菌。那些对庆大霉素耐药的菌株更有可能产生生物膜(P < 0.05)。在强生物膜产生菌中,ESBL、MBL、KPC和AmpC的检出率分别为51.8%、71.6%、43.8%和16.0%。
只有多粘菌素对鲍曼不动杆菌有效。碳青霉烯酶产生菌通常是强生物膜产生菌,对庆大霉素耐药的菌株更有可能产生生物膜。本研究结果可能有助于了解抗生素耐药机制,并为治疗多重耐药鲍曼不动杆菌感染提供有价值的信息。